Clinical trials: Etoposide, completed
Non-Hodgkin's Lymphoma
Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma
Primary Objective: Evaluate the clinical activity of the RT-PEPC combination regimen (rituximab, thalidomide, and prednisone, etoposide, procarbazine, cyclophosphamide) in patients with relapsed mantle cell lymphoma.
- Trial name
- NCT00151281
- Testing
- PEPC, Thalidomide, Rituximab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Weill Medical College of Cornell University
Small Cell Lung Cancer
Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC
This was a study to investigate the potential clinical benefit of trilaciclib (G1T28) in preserving the bone marrow and the immune system, and enhancing antitumor efficacy when administered with carboplatin, etoposide, and…
- Trial name
- NCT03041311
- Testing
- Trilaciclib, Carboplatin, Etoposide
- Where
- 45 sites in United States, Bulgaria and 5 more
- Volunteers
- 107 people
- Sponsor
- G1 Therapeutics, Inc.
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
This phase II clinical trial studies how well dasatinib followed by stem cell transplant works in treating older patients with newly diagnosed acute lymphoblastic leukemia.
- Trial name
- NCT01256398
- Testing
- Alemtuzumab, Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Hematopoietic Stem Cell Transplantation
- Where
- 101 sites in United States
- Volunteers
- 66 people
- Sponsor
- National Cancer Institute (NCI)
Neuroblastoma
Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma
This is a safety / feasibility trial evaluating the combination of a humanized anti-GD2 antibody (HU14.18K322A) manufactured at the Children's GMP, LLC at St.
- Trial name
- NCT01576692
- Testing
- Humanized anti-GD2 antibody, Chemotherapy, Cytokines
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- St. Jude Children's Research Hospital
Small Cell Lung Carcinoma
A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer
The purpose of this study is to determine the maximum tolerated dose (MTD) of BMS-833923 administered in combination with carboplatin and etoposide followed by BMS-833923 alone in subjects with extensive-stage Small Cell Lung…
- Trial name
- NCT00927875
- Testing
- BMS-833923, Carboplatin, Etoposide
- Where
- 6 sites in United States, Australia and 3 more
- Volunteers
- 5 people
- Sponsor
- Bristol-Myers Squibb
Lymphoma
Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma
This phase II clinical trial studies how well yttrium Y 90 ibritumomab tiuxetan, rituximab, and high-dose chemotherapy followed by peripheral blood stem cell transplant in treating patients with relapsed B-cell non-Hodgkin…
- Trial name
- NCT00695409
- Testing
- rituximab, carmustine, cytarabine
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- City of Hope Medical Center
Lymphoma
BeEAM Versus CEM in Lymphoma Patients as a Conditioning Regimen Before Autologous Hematopoietic Cell Transplantation
The proposed research aims to compare between BeEAM standard regimen and CEM as conditioning regimen in lymphoma patients in safety profile\& toxicity, infections (Febrile neutropenia) during transplant, time to engraftment…
- Trial name
- NCT05813132
- Testing
- BEAM Protocol, CEM protocol
- Where
- Egypt
- Volunteers
- 58 people
- Sponsor
- Rehab Werida
Childhood Germ Cell Tumor, Drug/Agent Toxicity by Tissue/Organ
Combination Chemotherapy Plus Amifostine in Treating Children With Malignant Germ Cell Tumors
RATIONALE: Chemotherapy drugs use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy.
- Conditions
- Childhood Germ Cell Tumor, Drug/Agent Toxicity by Tissue/Organ, Extragonadal Germ Cell Tumor, Ovarian Cancer
- Trial name
- NCT00003811
- Testing
- bleomycin sulfate, amifostine trihydrate, cisplatin
- Where
- 110 sites in United States, Australia and 4 more
- Volunteers
- 27 people
- Sponsor
- Children's Oncology Group
Lymphoma
Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed or Progressive B-Cell Diffuse Large Cell Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00052923
- Testing
- filgrastim, rituximab, carmustine
- Volunteers
- 427 people
- Sponsor
- Eastern Cooperative Oncology Group
Neuroblastoma
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00004188
- Testing
- filgrastim, carboplatin, cisplatin
- Where
- 96 sites in United States, Canada
- Volunteers
- 495 people
- Sponsor
- Children's Oncology Group
Cancer
Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as thrombopoietin and G-CSF may increase the number of immune cells found in…
- Trial name
- NCT00003597
- Testing
- recombinant human thrombopoietin, carboplatin, etoposide
- Where
- 24 sites in United States, Australia
- Volunteers
- 16 people
- Sponsor
- Children's Oncology Group
Aggressive Non-Hodgkin Lymphoma
Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas
This is a phase II study of metronomic chemotherapy in elderly non-fit patients (>65 years) with aggressive B-Cell lymphomas
- Trial name
- NCT03161054
- Testing
- Prednisone, Vinorelbine, Etoposide
- Where
- 10 sites in Italy
- Volunteers
- 21 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Small Cell Lung Cancer
G-Step: Gemcitabine Based Small-cell Lung Cancer Treatment in Elderly Patients
The purpose of this study is to describe the activity and toxicity of gemcitabine combined with four different drugs (carboplatin or cisplatin or etoposide or vinorelbine) as first line treatment of elderly patients with…
- Trial name
- G-Step (NCT00401609)
- Testing
- gemcitabine, vinorelbine, cisplatin
- Where
- 21 sites in Italy
- Volunteers
- 85 people
- Sponsor
- National Cancer Institute, Naples
Cardiac Toxicity, Lymphoma
Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00002827
- Testing
- bleomycin sulfate, filgrastim, dexrazoxane hydrochloride
- Where
- 39 sites in United States, Australia and 1 more
- Volunteers
- 294 people
- Sponsor
- Children's Oncology Group
Acute Lymphoblastic Leukemia
Allogeneic Stem Cell Transplantation (SCT) With Treosulfan, VP-16 and Cyclophosphamid for Patients With Acute Lymphoblastic Leukemia (ALL)
The present study is a multicenter, prospective phase II-study investigating the combination of treosulfan, etoposide, and cyclophosphamide as conditioning regimen for patients with acute lymphoblastic leukemia who are not…
- Trial name
- NCT00682305
- Testing
- Hematopoietic stem cell transplantation
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Prolymphocytic Leukemia, Recurrent Adult Hodgkin Lymphoma
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma
This phase I/II trial studies how well autologous stem cell transplant followed by donor stem cell transplant works in treating patients with lymphoma that has returned or does not respond to treatment.
- Conditions
- Prolymphocytic Leukemia, Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Hodgkin Lymphoma, Recurrent Childhood Non-Hodgkin Lymphoma
- Trial name
- NCT00005803
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation, Carmustine
- Where
- 5 sites in United States, Germany
- Volunteers
- 76 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myeloid Leukemia
Natural Killer (NK) Cell Transplantation for AML
The purpose of this study is to assess the safety and efficacy of infusing natural killer cells from a donor as treatment for patients with acute myeloid leukemia in remission or who have experienced relapse.
- Trial name
- NCT00187096
- Testing
- Cyclophosphamide, Fludarabine, Clofarabine, Etoposide, Interleukin-2, Natural Killer Cell Infusion, CliniMACS System
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- St. Jude Children's Research Hospital
Lymphoma
Etoposide in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of etoposide in treating patients with relapsed…
- Trial name
- NCT00002880
- Testing
- Etoposide phosphate
- Where
- 4 sites in United States
- Volunteers
- 53 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Thymoma and Thymic Carcinoma
Chemoradiotherapy for Limited Advanced Unresectable Thymic Epithelial Tumors
This study is designed to evaluate the feasibility and safety of concurrent chemoradiotherapy for limited advanced unresectable thymoma or thymic carcinoma.
- Trial name
- NCT02636556
- Testing
- concurrent chemoradiation
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Fudan University
Large B Cell Lymphoma
Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
This randomized phase III trial studies rituximab when given together with two different combination chemotherapy regimens to compare how well they work in treating patients with diffuse large B-cell non-Hodgkin's lymphoma.
- Trial name
- NCT00118209
- Testing
- rituximab, cyclophosphamide, doxorubicin
- Where
- 47 sites in United States
- Volunteers
- 524 people
- Sponsor
- Alliance for Clinical Trials in Oncology